Glycan in Cardiovascular Medicine
Creative Biolabs has persisted for many years in the field of antibody discovery and development for scientific research. We provide the best antibody production service for our customers all over the world. With the extensive expertise in the field of phage display technology, our scientists are pleased to construct high quality immunized antibody libraries and screen out high-affinity antibodies. Creative Biolabs now provides anti-glycan antibodies related to cardiovascular medicine for our clients.
Cardiovascular Disease
Cardiovascular disease (CVD) is the main cause of death globally and a class of diseases that associated with the heart or blood vessels, which including coronary artery diseases (CAD) such as angina and myocardial infarction. CVDs are spectrum diseases include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis. The underlying mechanisms are distinct according to different diseases.
The Role of Glycans in Cardiovascular Medicine
Cardiovascular diseases are related to high levels of low-density lipoprotein (LDL) cholesterol and decreased high-density lipoprotein (HDL) cholesterol. They can increase the risk of atherosclerotic lesions in the large arteries. The earliest phase of the development of atherosclerotic lesions (the fatty streak) due to the monocytes can enter the subendothelial regions of the blood vessels. This process also involves expression of P- and/or E-selectin on the endothelium, which binds to correctly glycosylated and sulfated P-selectin glycoprotein ligand-1 (PSGL-1) or sialyl Lewis x on circulating monocytes. In general, P-selectin deficiency in mice delays progression of atherosclerotic lesions. Oxidized lipids in LDL particles or inflammatory processes can lead to endothelial P-selectin in the early atheromatous plaque. Retention of LDLs in the early plaque probably involves their recognition of proteoglycans. This interaction is considered to cause irreversible structural alterations of LDL, potentiating oxidation and uptake by macrophages and smooth muscle cells. Besides, clusters of basic amino acids in apolipoprotein B (the protein moiety of LDL) tend to bind the negatively charged glycosaminoglycans of proteoglycans. Reduced sialylation of LDL was found in patients associated with coronary artery disease, desialylated LDL may be more easily taken up and incorporated into atheromatous plaques.
Fig.1 N-glycosylation associated with risk factors for dyslipidemia.1, 2
Features of Our Services
- High specificity and stability
- Optimal affinity, specificity, developability, and other properties
- Fully human nature
- More potent functionalities
In the field of antibody development, Creative Biolabs is a well-known expert who can use various advanced technologies to produce different types of antibodies with high affinity and specificity. Through routine immunization strategy, immunized antibody libraries can be generated with high diversity by our advanced screening technology. And several high-affinity antibodies can then be selected through biopanning techniques. Creative Biolabs has years of experience in the research and development of antibodies. Our scientists are confident in producing high-affinity anti-glycan antibodies to meet our clients’ most specific requirements and facilitate their projects. Please feel free to contact us for more details.
References:
- Loaeza-Reyes, Karen Julissa, et al. "An overview of glycosylation and its impact on cardiovascular health and disease." Frontiers in molecular biosciences 8 (2021): 751637.
- Distributed under Open Access license CC BY 4.0, without modification.